-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics to present BT8009 data in oral, poster sessions at ASCO meeting

PUBT·04/21/2026 14:36:06
Listen to the news
Bicycle Therapeutics to present BT8009 data in oral, poster sessions at ASCO meeting
  • Bicycle Therapeutics will present clinical updates on zelenectide pevedotin (BT8009) at ASCO 2026 in Chicago on May 29-June 2.
  • Rapid oral presentation on Duravelo-2 BT8009 with pembrolizumab in first-line locally advanced or metastatic urothelial carcinoma scheduled for June 1.
  • Poster presentations covering Duravelo-2 and Duravelo-1 BT8009 data in urothelial carcinoma set for May 31.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.